Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Approves Enasidenib for IDH2-Mutated AML

August 1st 2017

The FDA has approved enasidenib along with a companion diagnostic as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia.

CD19 CAR T-Cell Therapy Active in Ibrutinib-Refractory CLL

July 31st 2017

Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.

Emerging Developments in CML

July 29th 2017

Kendra Sweet, MD, discusses the various factors that must be taken into account when prescribing first-line therapies to patients with CML, novel studies, and TKI discontinuation.

FDA Grants Venetoclax Breakthrough Designation for AML Subpopulation

July 29th 2017

Venetoclax has received an FDA breakthrough therapy designation for use in combination with low dose cytarabine in treatment-naïve elderly patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

Expert Discusses Latest Developments in MPNs

July 26th 2017

Rami Komrokji, MD, shares his insight on the various types of MPNs, how these diseases can be diagnosed and managed, and the next steps needed to improve patient outcomes.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Expert Highlights Advances for Patients With PNH

July 25th 2017

Mohamed Kharfan-Dabaja, MD, discusses the future of PNH treatment, the various symptoms that can present in PNH, and the challenges that still remain for further improving outcomes.

Axicabtagene Ciloleucel Emerges as Potential Standard for Some NHL Patients

July 25th 2017

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

Frontline Obinutuzumab Recommended for EU Approval for Follicular Lymphoma

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma.

Midostaurin Recommended for EU Approval for AML

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of midostaurin to treat adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive.

Emerging Agents Poised to Transform AML Landscape

July 17th 2017

Jeffrey E. Lancet, MD, discusses new discoveries in the treatment of AML and challenges that remain in improving patient outcomes.

Expert Discusses State of CAR T-Cell Therapy in ALL

July 13th 2017

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL

July 12th 2017

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

ODAC Recommends Approval of Gemtuzumab Ozogamicin for Newly-Diagnosed AML

July 11th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 6-1 in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.

TP53 Mutations Have Independent Prognostic Value in MCL

July 11th 2017

Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.

Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

July 11th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

FDA Grants Dasatinib Priority Review for Children With Ph+ Chronic Phase CML

July 11th 2017

The FDA has accepted a supplemental new drug application for dasatinib (Sprycel) for use in children with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CP Ph+ CML).

Expert Discusses CD19 CAR T-Cell Therapy in B-Cell ALL

July 7th 2017

Eric Smith, MD, PhD, discusses the response to CD19 CAR T-cell therapy in B-cell ALL.

Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL

July 5th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities of the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

FDA Approves First Flow Cytometry-Based Diagnostic for Blood Cancer Detection

June 30th 2017

The FDA has approved ClearLLab multicolor reagents (T1, T2, B1, B2, M) for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.